B. Silver

发表

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Clinical Cancer Research.

Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin.

R. Fisher, J. Cossman, B. Silver, 1982, Cancer research.

Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

T. Mikkelsen, E. Wong, D. Schiff, 2010 .

Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.

D. Morton, C. Kung, S. Sheth, 2019, The New England journal of medicine.

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

C. Kung, Hua Yang, M. Goldwasser, 2018, Clinical pharmacology in drug development.

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

D. Morton, C. Kung, J. Hixon, 2016 .

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Juswinder Singh, T. Kipps, J. Gabrilove, 2012 .

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

T. Mikkelsen, D. Schiff, S. Kesari, 2015, Investigational New Drugs.

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

C. Kung, Hua Yang, B. Silver, 2015 .